Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niederle

Showing results (471-480 of 490) with videos related to

Pageof 49
Sort By:
Leukemia & Lymphoma|February 16, 2000
Bone marrow features and clinical findings in chronic myeloid leukemia--a comparative, multicenter, immunohistological and morphometric study on 614 patientsJ Thiele, H M Kvasnicka, A Schmitt-Graeff, et al.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|August 10, 2000
New radiopharmaceuticals for receptor scintigraphy and radionuclide therapyI Virgolini, T Traub, M Leimer, et al.
British Journal of Cancer|September 11, 2003
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trialC-H Köhne, R Catane, B Klein, et al.
Trials|February 7, 2014
Effectiveness of additional self-care acupressure for women with menstrual pain compared to usual care alone: using stakeholder engagement to design a pragmatic randomized trial and study protocolSusanne Blödt, Lena Schützler, Wenjing Huang, et al.
Blood|August 5, 2015
Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapyFabian Zohren, Ingmar Bruns, Sabrina Pechtel, et al.
The Lancet. Oncology|December 15, 2015
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trialMathias Rummel, Ulrich Kaiser, Christina Balser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinomaM Schlumberger, R Elisei, S Müller, et al.
Lancet (London, England)|February 26, 2013
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialMathias J Rummel, Norbert Niederle, Georg Maschmeyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Cabozantinib in progressive medullary thyroid cancerRossella Elisei, Martin J Schlumberger, Stefan P Müller, et al.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen|September 18, 2020
[EUROCRINE®: adrenal surgery 2015-2019- surprising initial results]J I Staubitz, T Clerici, P Riss, et al.
Pageof 49

Showing results (471-480 of 490) with videos related to

Sort By:
Pageof 49
Leukemia & Lymphoma|February 16, 2000
Bone marrow features and clinical findings in chronic myeloid leukemia--a comparative, multicenter, immunohistological and morphometric study on 614 patientsJ Thiele, H M Kvasnicka, A Schmitt-Graeff, et al.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|August 10, 2000
New radiopharmaceuticals for receptor scintigraphy and radionuclide therapyI Virgolini, T Traub, M Leimer, et al.
British Journal of Cancer|September 11, 2003
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trialC-H Köhne, R Catane, B Klein, et al.
Trials|February 7, 2014
Effectiveness of additional self-care acupressure for women with menstrual pain compared to usual care alone: using stakeholder engagement to design a pragmatic randomized trial and study protocolSusanne Blödt, Lena Schützler, Wenjing Huang, et al.
Blood|August 5, 2015
Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapyFabian Zohren, Ingmar Bruns, Sabrina Pechtel, et al.
The Lancet. Oncology|December 15, 2015
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trialMathias Rummel, Ulrich Kaiser, Christina Balser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinomaM Schlumberger, R Elisei, S Müller, et al.
Lancet (London, England)|February 26, 2013
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialMathias J Rummel, Norbert Niederle, Georg Maschmeyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Cabozantinib in progressive medullary thyroid cancerRossella Elisei, Martin J Schlumberger, Stefan P Müller, et al.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen|September 18, 2020
[EUROCRINE®: adrenal surgery 2015-2019- surprising initial results]J I Staubitz, T Clerici, P Riss, et al.
Pageof 49